Navigation Links
Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies
Date:5/26/2009

ll continue to experience seizures despite trying two or more AEDs
  • 200,000 new cases are diagnosed each year, a number that is expected to grow at a faster rate as the population ages

  • Important safety information about Vimpat in the U.S.

    Vimpat tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

    AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

    The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

    For more information, and prescribing information visit www.Vimpat.com or contact UCB at (800) 477-7877.

    Vimpat(R) is a registered trademark under license from Harris FRC Corporation.

        For further information
        Andrea Levin, Public Relations Manager, CNS, UCB
        Phone: 770-970-8352
        Em
    '/>"/>
    SOURCE UCB
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
    2. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
    3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
    4. ValueRich Report on AMDL/China Available on Web Site
    5. AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
    6. Arpida-Supported CME Symposium Available Online
    7. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
    8. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
    9. Neogen Launches Quickest Test Available for Tetracyclines in Milk
    10. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
    11. Canadas Best-Selling Soymilk Now Available with Marteks lifesDHA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on ... can be accessed via a live webcast on the United ...
    (Date:4/30/2015)... 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has commenced an underwritten public offering of ... the underwriters a 30-day option to purchase up to ... stock offered in the public offering. The offering is ... assurance as to whether or when the offering may ...
    (Date:4/30/2015)... , April 30, 2015  The Paul G. ... Distinguished Investigator (ADI) grants to six groups of researchers ... most challenging roadblocks in neuroscience: growing mature human brain ... a total of $7.5 million over three years.  ... and their research is especially significant because the field ...
    (Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Fleur’s ... multi-action product combining the benefits of makeup, skin ... This subtly tinted cream is designed with specific ... for an even complexion and a healthy glow. ...
    Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3
    ... talks are among those that will be presented by ... Laboratory at the American Physical Society meeting, March 10-14, ... Please note that the content of each talk is ... below. All of the research described below was funded ...
    ... Medco Health,Solutions, Inc. (NYSE: MHS ) announced ... principal amount of 6-1/8 percent senior notes due March,15, ... percent,senior notes due March 15, 2018 in an underwritten ... Securities LLC and Barclays,Capital Inc. are acting as representatives ...
    ... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
    Cached Biology Technology:News from the March 2008 American Physical Society Meeting 2News from the March 2008 American Physical Society Meeting 3News from the March 2008 American Physical Society Meeting 4News from the March 2008 American Physical Society Meeting 5Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8
    (Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
    (Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
    (Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
    Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
    ... are improving the taste, appearance and nutritional content of ... grow to $6 billion by 2017, according to a ... (IFT) Annual Meeting & Food Expo in Chicago. ... an immune disorder triggered by the ingestion of gluten ...
    ... tissue sustains irreparable damage in the wake of a ... and the cardiac muscle contains few stem cells, the ... fibrotic and cannot contract properly. In their search ... been exploring cardiac "patches" that could be transplanted into ...
    ... to cancer and other diseases, genetic testing, infectious proteins ... topics internationally renowned speakers will tackle at The EMBO ... from 21-24 September 2013. Sir Michael Stratton, Director ... Executive Officer of deCODE Genetics, and Thijn Brummelkamp, Group ...
    Cached Biology News:New technologies and ingredients provide better options for gluten-free eating 2A heart of gold 2Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam 2
    HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
    HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
    Recombinant Feline IL-5...
    ... Kits provide two highly efficient methods of ... plasmid preparation. By using the large-scale screen ... to do is to transfer partial colonies ... transformation plates into the solutions provided by ...
    Biology Products: